ArticleFrontiers in veterinary science2021
Evaluation of Chronic Kidney Disease Progression in Dogs With Therapeutic Management of Risk Factors.
Article in Frontiers in veterinary science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Supplementation withThe veterinary quarterly · 2026Article
- Transforming growth factor-β in kidney disease in dogs and cats: a review of the evidence of its role in renal fibrosis.Journal of veterinary internal medicine · 2026Review
- Incidence of kidney disease in the canine population treated at a small animal hospital in Uruguay.Brazilian journal of veterinary medicine · 2026Article
- Overall survival with beraprost in dogs with IRIS stage 2 chronic kidney disease.Frontiers in veterinary science · 2026Article
- Article
- Real-world data on canine chronic kidney disease in Greece: clinical and quality of life insights.Frontiers in veterinary science · 2025Article
- Replicating the real-world evidence methods available in human health to assess burden and outcomes for dogs with chronic kidney disease, their owners, and the veterinary healthcare system in the United States of America.Frontiers in veterinary science · 2025Article
- Serum and Urinary Uromodulin in Dogs with Early Chronic Kidney Disease vs. Healthy Canine Population.Animals : an open access journal from MDPI · 2024Article
- A comprehensive analysis of albuminuria in canine chronic kidney disease.Veterinary medicine and science · 2024Article
- Untargeted metabolomic profiling of serum from client-owned cats with early and late-stage chronic kidney disease.Scientific reports · 2024Article
- Euthanasia and Pain in Canine Patients with Terminal and Chronic-Degenerative Diseases: Ethical and Legal Aspects.Animals : an open access journal from MDPI · 2023Review
- The first study on urinary loss of iron and transferrin in association with proteinuria in dogs with chronic kidney disease.Veterinary world · 2023Article
- Evaluation of progression of chronic kidney disease in dogs with myxomatous mitral valve disease.Frontiers in veterinary science · 2023Article
- The Increase in Circulating Levels of Pro-Inflammatory Chemokines, Cytokines, and Complement C5 in Canines with Impaired Kidney Function.Current issues in molecular biology · 2022Article
- Analysis of survival among biopsy-determined categories of kidney disease in dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research was performed to describe the characteristics of the progression of naturally occurring chronic kidney disease (CKD) in dogs, together with the management of identified risk factors, following the International Renal Interest Society recommendations. Dogs diagnosed and staged with CKD, and with a longitudinal follow-up from the moment of diagnosis of up to a maximum of 730 days, were included. A total of 545 dogs that presented risk factors for the development of CKD were analyzed, out of which 36 met the inclusion criteria. Advanced age was identified in 80.6% of cases. Initiation risk factors were represented by inflammatory/infectious diseases, history of anesthetic-surgical procedures, heart disease, neoplasms, endocrinopathies, and exposure to nephrotoxic drugs. During the follow-up period, progression of CKD was identified in 47.2% of the cases, being more salient in advanced stages. Serum symmetric dimethyl arginine (SDMA) was the only glomerular filtration rate (GFR) marker which displayed differences among studied times during early stages of CKD, associated with the disease progression and decline of renal function. A significant difference between the survival curves in early and advanced CKD stages was observed. The factors related to decreased survival were hyperphosphatemia, anemia, and low body condition score (BCS). No differences were found between the presence of arterial hypertension and renal proteinuria and decreased survival. Furthermore, CKD diagnosis based on the persistent finding of abnormalities in early disease markers, such as serum symmetric dimethyl arginine increase and/or renal proteinuria, and timely therapeutic management of risk factors, allowed for CKD stabilization, reducing progression to advanced stages, and favoring higher survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.